Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.46 |
| ▸ | THRA | P10827 | 14/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.38 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695738 | 0.92 | THRB (0.53) | THRBTHRA | |
| SCHEMBL6695033 | 0.89 | THRB (0.59) | THRBTHRA | |
| SCHEMBL6700899 | 0.85 | THRB (0.50) | THRBTHRA | |
| SCHEMBL6692015 | 0.81 | THRB (0.47) | THRBTHRAEGLN1PIN1 | |
| SCHEMBL6693202 | 0.80 | THRA (0.54) | THRBTHRA | |
| Methane SCHEMBL6690821 | 0.79 | THRA (0.53) | THRBTHRA | |
| SCHEMBL6700087 | 0.79 | THRB (0.43) | THRBTHRA | |
| SCHEMBL6695481 | 0.78 | THRA (0.37) | THRBTHRAPIN1 | |
| SCHEMBL6695043 | 0.78 | THRB (0.52) | THRBTHRA | |
| SCHEMBL7258380 | 0.77 | THRA (0.39) | THRBTHRAPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003094845-A2 | PYRIDINE-BASED THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | THRB 2/4885THRA 3/4885EGLN1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.